Imagion Biosystems is pleased to announce a pro-rata renounceable rights issue (Offer) to fund the manufacture of the nanoparticle material, the undertaking of a first-in-human study (where sufficient capital is raised), and for general working capital purposes.
Read the Pro-Rata Renounceable Rights Issue.
[Video] Shareholder Webinar Recording | August 15, 2024
August 22, 2024
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation